A Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Patients with Alzheimer's Disease

G.M. Petracca, E. Chemerinski, Sergio Starkstein

    Research output: Contribution to journalArticle

    112 Citations (Scopus)

    Abstract

    Objective: To examine the efficacy of fluoxetine in the treatment of depression in patients with probable Alzheimer's disease (AD). Methods: This double-blind, parallel-design study included a consecutive series of 41 AD subjects meeting DSM-IV criteria for major or minor depression who were randomized to receive fluoxetine (up to 40 mg/day) or identical-appearing placebo. All patients received biweekly evaluations consisting of the Hamilton Depression Scale (HAM-D) and the Clinical Global Impression as primary efficacy measures, and the Mini-Mental State Exam, Hamilton Rating Scale for Anxiety, and the Functional Independence Measure as secondary efficacy measures. Results: Complete remission of depression was found in 47% of subjects treated with fluoxetine and in 33% of subjects treated with placebo. Both the fluoxetine and the placebo groups showed a significant decline in HAM-D scores over time, but the magnitude of mood improvement was similar for both groups. Fluoxetine was well tolerated, and most side effects were mild. Conclusion: Fluoxetine treatment for depression in AD did not differ significantly from treatment with placebo. Our study also confirms the presence of a placebo effect in the treatment of depression in AD.
    Original languageEnglish
    Pages (from-to)233-240
    JournalInternational Psychogeriatrics
    Volume13
    Issue number2
    DOIs
    Publication statusPublished - 2001

    Fingerprint

    Fluoxetine
    Alzheimer Disease
    Placebos
    Depression
    Placebo Effect
    Therapeutics
    Double-Blind Method
    Diagnostic and Statistical Manual of Mental Disorders
    Anxiety

    Cite this

    @article{7ed2b3a2ad2944f7b1313d62e677dc57,
    title = "A Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Patients with Alzheimer's Disease",
    abstract = "Objective: To examine the efficacy of fluoxetine in the treatment of depression in patients with probable Alzheimer's disease (AD). Methods: This double-blind, parallel-design study included a consecutive series of 41 AD subjects meeting DSM-IV criteria for major or minor depression who were randomized to receive fluoxetine (up to 40 mg/day) or identical-appearing placebo. All patients received biweekly evaluations consisting of the Hamilton Depression Scale (HAM-D) and the Clinical Global Impression as primary efficacy measures, and the Mini-Mental State Exam, Hamilton Rating Scale for Anxiety, and the Functional Independence Measure as secondary efficacy measures. Results: Complete remission of depression was found in 47{\%} of subjects treated with fluoxetine and in 33{\%} of subjects treated with placebo. Both the fluoxetine and the placebo groups showed a significant decline in HAM-D scores over time, but the magnitude of mood improvement was similar for both groups. Fluoxetine was well tolerated, and most side effects were mild. Conclusion: Fluoxetine treatment for depression in AD did not differ significantly from treatment with placebo. Our study also confirms the presence of a placebo effect in the treatment of depression in AD.",
    author = "G.M. Petracca and E. Chemerinski and Sergio Starkstein",
    year = "2001",
    doi = "10.1017/S104161020100761X",
    language = "English",
    volume = "13",
    pages = "233--240",
    journal = "International Psychogeriatrics",
    issn = "1041-6102",
    publisher = "Cambridge University Press",
    number = "2",

    }

    A Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Patients with Alzheimer's Disease. / Petracca, G.M.; Chemerinski, E.; Starkstein, Sergio.

    In: International Psychogeriatrics, Vol. 13, No. 2, 2001, p. 233-240.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - A Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Patients with Alzheimer's Disease

    AU - Petracca, G.M.

    AU - Chemerinski, E.

    AU - Starkstein, Sergio

    PY - 2001

    Y1 - 2001

    N2 - Objective: To examine the efficacy of fluoxetine in the treatment of depression in patients with probable Alzheimer's disease (AD). Methods: This double-blind, parallel-design study included a consecutive series of 41 AD subjects meeting DSM-IV criteria for major or minor depression who were randomized to receive fluoxetine (up to 40 mg/day) or identical-appearing placebo. All patients received biweekly evaluations consisting of the Hamilton Depression Scale (HAM-D) and the Clinical Global Impression as primary efficacy measures, and the Mini-Mental State Exam, Hamilton Rating Scale for Anxiety, and the Functional Independence Measure as secondary efficacy measures. Results: Complete remission of depression was found in 47% of subjects treated with fluoxetine and in 33% of subjects treated with placebo. Both the fluoxetine and the placebo groups showed a significant decline in HAM-D scores over time, but the magnitude of mood improvement was similar for both groups. Fluoxetine was well tolerated, and most side effects were mild. Conclusion: Fluoxetine treatment for depression in AD did not differ significantly from treatment with placebo. Our study also confirms the presence of a placebo effect in the treatment of depression in AD.

    AB - Objective: To examine the efficacy of fluoxetine in the treatment of depression in patients with probable Alzheimer's disease (AD). Methods: This double-blind, parallel-design study included a consecutive series of 41 AD subjects meeting DSM-IV criteria for major or minor depression who were randomized to receive fluoxetine (up to 40 mg/day) or identical-appearing placebo. All patients received biweekly evaluations consisting of the Hamilton Depression Scale (HAM-D) and the Clinical Global Impression as primary efficacy measures, and the Mini-Mental State Exam, Hamilton Rating Scale for Anxiety, and the Functional Independence Measure as secondary efficacy measures. Results: Complete remission of depression was found in 47% of subjects treated with fluoxetine and in 33% of subjects treated with placebo. Both the fluoxetine and the placebo groups showed a significant decline in HAM-D scores over time, but the magnitude of mood improvement was similar for both groups. Fluoxetine was well tolerated, and most side effects were mild. Conclusion: Fluoxetine treatment for depression in AD did not differ significantly from treatment with placebo. Our study also confirms the presence of a placebo effect in the treatment of depression in AD.

    U2 - 10.1017/S104161020100761X

    DO - 10.1017/S104161020100761X

    M3 - Article

    VL - 13

    SP - 233

    EP - 240

    JO - International Psychogeriatrics

    JF - International Psychogeriatrics

    SN - 1041-6102

    IS - 2

    ER -